Cargando…
Efficacy of a Novel Pleiotropic MMP-Inhibitor, CMC2.24, in a Long-Term Diabetes Rat Model with Severe Hyperglycemia-Induced Oral Bone Loss
PURPOSE: CMC2.24, a novel 4-(phenylaminocarbonyl)-chemically-modified-curcumin, is a pleiotropic MMP-Inhibitor of various inflammatory/collagenolytic diseases including periodontitis. This compound has demonstrated efficacy in host modulation therapy along with improved resolution of inflammation in...
Autores principales: | Bhatt, Heta Dinesh, Golub, Lorne M, Lee, Hsi-Ming, Kim, Jihwan, Zimmerman, Thomas, Deng, Jie, Hong, Houlin, Johnson, Francis, Gu, Ying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969803/ https://www.ncbi.nlm.nih.gov/pubmed/36860795 http://dx.doi.org/10.2147/JIR.S399043 |
Ejemplares similares
-
A novel modified-curcumin 2.24 resolves inflammation by promoting M2 macrophage polarization
por: Deng, Jie, et al.
Publicado: (2023) -
Chemically-Modified Curcumin 2.24: A Novel Systemic Therapy for Natural Periodontitis in Dogs
por: Deng, Jie, et al.
Publicado: (2020) -
Prostate Cancer Stem Cell-Targeted Efficacy of a New-Generation Taxoid, SBT-1214 and Novel Polyenolic Zinc-Binding Curcuminoid, CMC2.24
por: Botchkina, Galina I., et al.
Publicado: (2013) -
The Maximum-Tolerated Dose and Pharmacokinetics of a Novel Chemically Modified Curcumin in Rats
por: Bhatt, Heta Dinesh, et al.
Publicado: (2022) -
Novel Hydrogenated Derivatives of Chemically Modified Curcumin CMC2.24 Are Potent Inhibitors of Melanogenesis in an In Vitro Model: Influence of Degree of Hydrogenation
por: Goenka, Shilpi
Publicado: (2023)